Accuracy validation of adjuvant! online in Taiwanese breast cancer patients - a 10-year analysis
Adjuvant! Online ( http://www.adjuvantonline.com) is an Internet-based software program that allows clinicians to make predictions about the benefits of adjuvant therapy and 10-year survival probability for early-stage breast cancer patients. This model has been validated in Western countries such as the United States, United Kingdom, Canada, Germany, and Holland. The aim of our study was to investigate the performance and accuracy of Adjuvant! Online in a cohort of Taiwanese breast cancer patients.
Data on the prognostic factors and clinical outcomes of 559 breast cancer patients diagnosed at the National Cheng Kung University Hospital in Tainan between 1992 and 2001 were enrolled in the study. Comprehensive demographic, clinical outcome data, and adjuvant treatment data were entered into the Adjuvant! Online program. The outcome prediction at 10 years was compared with the observed and predicted outcomes using Adjuvant! Online.
Comparison between low- and high-risk breast cancer patient subgroups showed significant differences in tumor grading, tumor size, and lymph node status (p < 0.0001). The mean 10-year predicted death probability in 559 patients was 19.44%, and the observed death probability was 15.56%. Comparison with the Adjuvant! Online-predicted breast cancer-specific survival (BCSS) showed significant differences in the whole cohort (p < 0.001). In the low-risk subgroup, the predicted and observed outcomes did not differ significantly (3.69% and 3.85%, respectively). In high-risk patients, Adjuvant! Online overestimated breast cancer-specific survival (p = 0.016); the predicted and observed outcomes were 21.99% and 17.46%, respectively.
Adjuvant! Online accurately predicted 10-year outcomes and assisted in decision making about adjuvant treatment in low-risk breast cancer patients in our study, although the results were less accurate in the high-risk subgroup. Development of a prognostic program based on a national database should be considered, especially for high-risk breast cancer patients in Taiwan.
- Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009,20(8):1319–1329. CrossRef
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011,22(8):1736–1747. CrossRef
- National Comprehensive Cancer Network Web Site. http://www.nccn.org/index.asp
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005,365(9472):1687–1717. CrossRef
- Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992,22(3):207–219. CrossRef
- Lyman GH, Cosler LE, Kuderer NM, Hornberger J: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007,109(6):1011–1018. CrossRef
- Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001,19(4):980–991.
- Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM: A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 2006,15(11):1001–1013. CrossRef
- Chang TW, Kuo YL: A model building exercise of mortality risk for Taiwanese women with breast cancer. BMC Med Inform Decis Mak 2010, 10:43. CrossRef
- Adjuvant! Online Web Site. http://www.adjuvantonline.com
- National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Web Site . http://seer.cancer.gov/
- Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005,23(12):2716–2725. CrossRef
- Hosmer D, Lemeshow S: Applied logistic regression. New York: Wiley; 1989.
- Lundin M, Lundin J, Burke HB, Toikkanen S, Pylkkanen L, Joensuu H: Artificial neural networks applied to survival prediction in breast cancer. Oncology 1999,57(4):281–286. CrossRef
- Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005,11(5):313–324.
- Campbell HE, Taylor MA, Harris AL, Gray AM: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 2009,101(7):1074–1084. CrossRef
- Cufer T: Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online. Ann Oncol 2008,19(7):vii41-vii45. CrossRef
- Nowak V, Ah-See M, Ravichandran D: Breast cancer multidisciplinary team adjuvant therapy decision making and adjuvant! Online. Clin Oncol (R Coll Radiol) 2010,22(1):87–88. CrossRef
- Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsasser A, Gehrmann M, et al.: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer–comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009,20(2):258–264. CrossRef
- Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van't Veer LJ, Ravdin PM: Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009,10(11):1070–1076. CrossRef
- Bhoo-Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Ho GF, Looi LM, Bulgiba AM, van der Graaf Y, Verkooijen HM: Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer 2012,48(7):982–989. CrossRef
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6947/12/108/prepub
- Accuracy validation of adjuvant! online in Taiwanese breast cancer patients - a 10-year analysis
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Medical Informatics and Decision Making
- Online Date
- September 2012
- Online ISSN
- BioMed Central
- Additional Links
- Adjuvant! Online
- Breast cancer
- Mortality prediction
- Author Affiliations
- 1. Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan and Dou-Liou Branch, 138 Sheng Li Road, Tainan, 704, Taiwan
- 2. Comprehensive Breast Cancer Center, Changhua Christian Hospital, 135 Nanxiao St, Changhua, 500, Taiwan
- 3. Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan, 704, Taiwan